News

News & Press Releases

2013
CONRAD at Women Deliver
March 21, 2013
CONRAD Job Openings
March 4, 2013
CONRAD Statement on VOICE Results
February 12, 2013
Enter PATH's Female Condom Film Contest
February 1, 2013
PLoS ONE article concludes that vaginal tenofovir gel provides higher levels of drug in the vaginal tissue compared to oral dosing
October 16, 2012
NEW HIV PREVENTION TECHNOLOGY SHOWS PROMISE Intravaginal ring delivers tenofovir over 90 days
August 7, 2012
CONRAD Announces New Leadership
May 11, 2012
FDA Advisory Panel Backs Approval of Truvada for HIV Prevention
May 3, 2012
CONRAD's Henry Gabelnick and Gustavo Doncel Discuss Multi-Purpose Prevention Technologies
March 8, 2012
Woman's Condom Makes Top 50 Ideas List
March 6, 2012
MTN presents Phase I data on rectal formulation of tenofovir gel at CROI
February 16, 2012
WHO upholds guidance on hormonal contraceptive use and HIV
January 9, 2012
Dr. Jill Schwartz discusses the SILCS Diaphragm in Contraceptive Technology Today
November 25, 2011
VOICE Trial Indicates Daily Dosing of Tenofovir Gel Ineffective
October 26, 2011
FACTS 001 Study Announces Enrollment of First Study Participant
October 13, 2011
USAID Awards Cooperative Agreement to CONRAD for Multipurpose Prevention Study
September 28, 2011
CONRAD Statement on VOICE DSMB
September 16, 2011
CONRAD PRESENTS RESULTS OF PIVOTAL CONTRACEPTIVE STUDY AT REPRODUCTIVE HEALTH 2011
July 26, 2011
IAS Rome 2011: CONRAD Teams up with Global Campaign for Microbicides and South Africa's Department of Science and Technology
July 13, 2011
CONRAD Statement on Pre-Exposure Prophylaxis Trials
June 14, 2011
NEXT STEPS FOR TENOFOVIR GEL: CONRAD AND TIA SIGN LICENSE AGREEMENT
June 9, 2011
CAPRISA Leadership Team Wins DST Award

1911 North Fort Myer Drive, Suite 900, Arlington, VA 22209   T: 703.524.4744 | info@conrad.org